You are viewing the site in preview mode
Skip to main content
|
Characteristics
|
All
|
Low risk exacerbator (LRE)
|
High risk exacerbator (HRE)
|
PFT I
|
PFT II
|
|---|
|
Number of patients
|
78
|
60
|
18
|
43
|
35
|
|
Age (years)
|
|
Range
|
40–93
|
40–91
|
52–93
|
40–90
|
52–93
|
|
Mean ± s.e.m
|
74.17 ± 1.446
|
73.63 ± 1.673
|
75.94 ± 2.889
|
72.37 ± 2.020
|
76.37 ± 2.025
|
|
Gender
|
|
Male
|
68 (87.2%)
|
50 (83.3%)
|
18 (100%)
|
36 (83.7%)
|
32 (91.4%)
|
|
Female
|
10 (12.8%)
|
10 (16.7%)
|
0 (0%)
|
7 (16.3%)
|
3 (8.6%)
|
|
FEV1 (% predicted)
|
|
Range
|
24.6–97.9
|
30.5–97.9
|
24.6–73.8
|
50.0–97.9
|
24.6–49.6
|
|
Mean ± s.e.m
|
53.24 ± 1.682
|
55.73 ± 1.902
|
44.95 ± 2.901
|
63.62 ± 1.702
|
40.49 ± 1.097
|
|
FEV1/FVC
|
|
Range
|
37.31–69.54
|
45.33–69.54
|
37.31–66.86
|
52.30–69.54
|
37.31–69.18
|
|
Mean ± s.e.m
|
59.59 ± 0.767
|
60.98 ± 0.783
|
54.95 ± 1.673
|
62.45 ± 0.738
|
56.07 ± 1.218
|
|
Current smoking
|
|
No
|
17 (21.8%)
|
13 (21.7%)
|
4 (22.2%)
|
11 (25.6%)
|
6 (17.1%)
|
|
Yes
|
61 (78.2%)
|
47 (78.3%)
|
14 (77.8%)
|
32 (74.4%)
|
29 (82.9%)
|
|
Medication
|
|
LAB
|
31 (39.7%)
|
28 (46.7%)
|
3 (16.7%)
|
28 (65.1%)
|
3 (8.6%)
|
|
LABA + ICS
|
45 (57.7%)
|
30 (50.0%)
|
15 (83.3%)
|
13 (30.2%)
|
32 (91.4%)
|
|
No
|
2 (2.6%)
|
2 (3.3%)
|
0 (0%)
|
2 (4.7%)
|
0 (0%)
|
- LRE low risk exacerbator, HRE high risk exacerbator, PFT pulmonary function test, PFT I FEV1 ≥ 50, PFT II FEV1 < 50, FEV1 forced expiratory volume in the first second, FVC forced vital capacity, LAB long-acting bronchodilator, LABA long-acting β2 agonists, ICS inhaled corticosteroid
